The Enhanced Responder Phenomenon with ME/CFS and Oxaloacetate Therapy

More than 17 million people worldwide have ME/CFS and chronic fatigue. As medical care scrambles to find more effective treatments, the Bateman Horne Center finds that Oxaloacetate Therapy, under the brand name Oxaloacetate CFS, yields a significant average reduction in fatigue from baseline of 25-35%. 

While all patients in the oxaloacetate treatment group saw a significant shift to lower fatigue and protection against “energy crashes”, some patients were described by scientists as “Enhanced Responders”. In a double-blinded, controlled clinical trial, 40.5% of the oxaloacetate group patients were Enhanced Responders with an average fatigue reduction of 63% in addition to the protective shift in energy. This massive difference in fatigue levels was life changing for many participants of the study and offers a lot of promise to the global ME/CFS community. 

But what makes this 40.5% population of people with ME/CFS enhanced responders? Will understanding the biological mechanisms of oxaloacetate therapy, ME/CFS and “enhanced responders” make it possible to bring these enhanced benefits to 100% of the ME/CFS population?

In response to this study, Researchers at Standford University are asking this same question, currently running metabolomic tests of the blood drawn from this study’s participants and comparing enhanced responder levels to the general patient population. The work in metabolic fatigue flows from 20 years of scientific research in metabolomic mechanisms.

We’re eager to see the results and are encouraged by the attention oxaloacetate therapy is receiving in the ME/CFS medical research community.